{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-263529","form_type":"8-K","ticker":"OFIX","cik":"0000884624","company_name":"Orthofix Medical Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.473287+00:00","generated_at":"2026-05-17T00:47:36.729788+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Orthofix Q3 pro forma net sales up 5.7%; adj EBITDA margin expands to 12.1%","bullets":["Pro forma net sales $203.4M, +5.7% constant currency vs Q3 2024; reported net sales $205.6M.","Non-GAAP adj EBITDA $24.6M (12.1% margin) vs $19.2M (9.8%) prior year; seven consecutive quarters of expansion.","U.S. Spine Fixation sales +8%, Bone Growth Therapies +6%, Global Orthopedics constant currency +6%.","FY2025 pro forma net sales guidance narrowed to $810-814M; adj EBITDA guidance raised low end to $84-86M.","Free cash flow positive $2.5M in Q3; positive FCF expected for full year 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-263529","json":"https://secwatch.observer/filing/0001193125-25-263529.json","markdown":"https://secwatch.observer/filing/0001193125-25-263529.md","text":"https://secwatch.observer/filing/0001193125-25-263529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/884624/000119312525263529/0001193125-25-263529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/884624/000119312525263529/ofix-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:47:36.729788+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}